AUTHOR=Zhang Kunlong , Gao Li , Wang Jianwei , Chu Xinran , Zhang Zimu , Zhang Yongping , Fang Fang , Tao Yanfang , Li Xiaolu , Tian Yuanyuan , Li Zhiheng , Sang Xu , Ma Li , Lu Lihui , Chen Yanling , Yu Juanjuan , Zhuo Ran , Wu Shuiyan , Pan Jian , Hu Shaoyan TITLE=A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells JOURNAL=Pathology and Oncology Research VOLUME=28 YEAR=2022 URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2022.1610447 DOI=10.3389/pore.2022.1610447 ISSN=1532-2807 ABSTRACT=

Acute myeloid leukemia (AML) represents an aggressive hematopoietic malignancy with a prognosis inferior to that of other leukemias. Recent targeted therapies offer new opportunities to achieve better treatment outcomes. However, due to the complex heterogeneity of AML, its prognosis remains dismal. In this study, we first identified the correlation between high expression of BRD4 and overall survival of patients with AML. Targeted degradation of BRD2, BRD3, and BRD4 proteins by dBET1, a proteolysis-targeting chimera (PROTAC) against the bromodomain and extra-terminal domain (BET) family members, showed cytotoxic effects on Kasumi (AML1-ETO), NB4 (PML-RARa), THP-1 (MLL-AF9), and MV4-11 (MLL-AF4) AML cell lines representing different molecular subtypes of AML. Furthermore, we determined that dBET1 treatment arrested cell cycling and enhanced apoptosis and c-MYC was identified as the downstream target. Collectively, our results indicated that dBET1 had broad anti-cancer effects on AML cell lines with different molecular lesions and provided more benefits to patients with AML.